TABLE OF CONTENTS
Volume 18, Issue 3 (March 2004)
Mini Review |
Spotlight |
Molecular Targets For Therapy (MTT) |
Original Manuscripts |
Spotlight Correspondence |
Correspondence |
Corrigendum
Reviews
Acute promyelocytic leukemia: where does it stem from? FREE
D Grimwade and T Enver
Leukemia 18: 375-384; advance online publication, January 22, 2004; doi:10.1038/sj.leu.2403234
Nucleoside transporters in chronic lymphocytic leukaemia FREE
M Pastor-Anglada, M Molina-Arcas, F J Casado, B Bellosillo, D Colomer and J Gil
Leukemia 18: 385-393; advance online publication, January 22, 2004; doi:10.1038/sj.leu.2403271
Mini Review
CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review FREE
M C Béné, G Castoldi, W Knapp, G M Rigolin, L Escribano, P Lemez, W-D Ludwig, E Matutes, A Orfao, F Lanza and M van't Veer on behalf of EGIL, European Group on Immunological Classification of Leukemias
Leukemia 18: 394-400; advance online publication, December 11, 2003; doi:10.1038/sj.leu.2403250
Spotlight
P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate FREE
T Illmer, M Schaich, U Platzbecker, J Freiberg-Richter, U Oelschlägel, M von Bonin, S Pursche, T Bergemann, G Ehninger and E Schleyer
Leukemia 18: 401-408; advance online publication, January 15, 2004; doi:10.1038/sj.leu.2403257
Imatinib sensitizes CLL lymphocytes to chlorambucil FREE
R Aloyz, K Grzywacz, Z-Y Xu, M Loignon, M A Alaoui-Jamali and L Panasci
Leukemia 18: 409-414; advance online publication, December 18, 2003; doi:10.1038/sj.leu.2403247
Molecular Targets For Therapy (MTT)
Identification of a gene element essential for leukemia-specific expression of transgenes FREE
N Hosen, M Yanagihara, T Nakazawa, K Kanato, S Nishida, T Shirakata, M Asada, T Masuda, Y Taniguchi, M Kawakami, A Tsuboi, K Ikegame, Y Oka, H Ogawa, I Kawase, Y Oji and H Sugiyama
Leukemia 18: 415-419; advance online publication, January 22, 2004; doi:10.1038/sj.leu.2403260
Original Manuscripts
Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia FREE
M D Tischkowitz, N V Morgan, D Grimwade, C Eddy, S Ball, I Vorechovsky, S Langabeer, R Stöger, S V Hodgson and C G Mathew
Leukemia 18: 420-425; advance online publication, January 29, 2004; doi:10.1038/sj.leu.2403280
Abundant expression of fibronectin is a major feature of leukemic dendritic cells differentiated from patients with acute myeloid leukemia FREE
A Vialle-Castellano, B Gaugler, M Mohty, D Isnardon, N van Baren and D Olive
Leukemia 18: 426-433; advance online publication, January 22, 2004; doi:10.1038/sj.leu.2403273
Upregulation of asparagine synthetase fails to avert cell cycle arrest induced by L-asparaginase in TEL/AML1-positive leukaemic cells FREE
O Krejci, J Starkova, B Otova, J Madzo, M Kalinova, O Hrusak and J Trka
Leukemia 18: 434-441; advance online publication, January 15, 2004; doi:10.1038/sj.leu.2403259
Retinoic acid syndrome in NOD/scid mice induced by injecting an acute promyelocytic leukemia cell line FREE
M Ninomiya, H Kiyoi, M Ito, Y Hirose, M Ito and T Naoe
Leukemia 18: 442-448; advance online publication, January 29, 2004; doi:10.1038/sj.leu.2403284
Differentially expressed genes in adult familial myelodysplastic syndromes FREE
A Pradhan, A Mijovic, K Mills, P Cumber, N Westwood, G J Mufti and F V Rassool
Leukemia 18: 449-459; advance online publication, January 22, 2004; doi:10.1038/sj.leu.2403265
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes FREE
M Stadler, U Germing, K-O Kliche, K M Josten, R Kuse, W-K Hofmann, H Schrezenmeier, J Novotny, O Anders, H Eimermacher, W Verbeek, H-H Kreipe, H Heimpel, C Aul and A Ganser
Leukemia 18: 460-465; advance online publication, January 8, 2004; doi:10.1038/sj.leu.2403239
Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia FREE
L-Y Shih, C-F Huang, P-N Wang, J-H Wu, T-L Lin, P Dunn and M-C Kuo
Leukemia 18: 466-475; advance online publication, January 22, 2004; doi:10.1038/sj.leu.2403274
Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis FREE
A Cuneo, G M Rigolin, R Bigoni, C De Angeli, A Veronese, F Cavazzini, A Bardi, M G Roberti, E Tammiso, P Agostini, M Ciccone, M Della Porta, A Tieghi, L Cavazzini, M Negrini and G Castoldi
Leukemia 18: 476-483; advance online publication, December 18, 2003; doi:10.1038/sj.leu.2403242
Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia FREE
J Lundin, A Porwit-MacDonald, E D Rossmann, C Karlsson, P Edman, M R Rezvany, E Kimby, A Österborg and H Mellstedt
Leukemia 18: 484-490; advance online publication, January 22, 2004; doi:10.1038/sj.leu.2403258
Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation FREE
P Menendez, A Vargas, C Bueno, S Barrena, J Almeida, M de Santiago, A López, S Roa, J F San Miguel and A Orfao
Leukemia 18: 491-498; advance online publication, January 15, 2004; doi:10.1038/sj.leu.2403231
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse FREE
E Coustan-Smith, A Gajjar, N Hijiya, B I Razzouk, R C Ribeiro, G K Rivera, J E Rubnitz, J T Sandlund, M Andreansky, M L Hancock, C-H Pui and D Campana
Leukemia 18: 499-504; doi:10.1038/sj.leu.2403283
PKC 
mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylation FREE
T Jiffar, S Kurinna, G Suck, D Carlson-Bremer, M R Ricciardi, M Konopleva, M Andreeff and P P Ruvolo
Leukemia 18: 505-512; advance online publication, January 22, 2004; doi:10.1038/sj.leu.2403275
Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein 
anti-CD3 diabody FREE
Y Gao, D Xiong, M Yang, H Liu, H Peng, X Shao, Y Xu, C Xu, D Fan, L Qin, C Yang and Z Zhu
Leukemia 18: 513-520; doi:10.1038/sj.leu.2403267
In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype FREE
N L Ramakers-van Woerden, H B Beverloo, A J P Veerman, B M Camitta, A H Loonen, E R van Wering, R M Slater, J Harbott, M L den Boer, W D Ludwig, O A Haas, G E Janka-Schaub and R Pieters
Leukemia 18: 521-529; advance online publication, January 8, 2004; doi:10.1038/sj.leu.2403253
Glucocorticoid receptor alpha, beta and gamma expression vs in vitro glucocorticod resistance in childhood leukemia FREE
E G Haarman, G J L Kaspers, R Pieters, M M A Rottier and A J P Veerman
Leukemia 18: 530-537; advance online publication, January 15, 2004; doi:10.1038/sj.leu.2403225
Establishment and phenotypic characterization of human U937 cells with inducible P210 BCR/ABL expression reveals upregulation of CEACAM1 (CD66a) FREE
P Håkansson, C Lassen, T Olofsson, B Baldetorp, A Karlsson, U Gullberg and T Fioretos
Leukemia 18: 538-547; advance online publication, January 8, 2004; doi:10.1038/sj.leu.2403255
TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-independent STAT5 signal pathways FREE
T Kanie, A Abe, T Matsuda, Y Kuno, M Towatari, T Yamamoto, H Saito, N Emi and T Naoe
Leukemia 18: 548-555; advance online publication, January 29, 2004; doi:10.1038/sj.leu.2403266
DNA microarray analysis of natural killer cell-type lymphoproliferative disease of granular lymphocytes with purified CD3-CD56+ fractions FREE
Y L Choi, H Makishima, J Ohashi, Y Yamashita, R Ohki, K Koinuma, J Ota, Y Isobe, F Ishida, K Oshimi and H Mano
Leukemia 18: 556-565; advance online publication, January 22, 2004; doi:10.1038/sj.leu.2403261
Impaired stem cell function of CD34+ cells selected by two different immunomagnetic beads systems FREE
T Kimura, H Minamiguchi, J Wang, H Kaneko, H Nakagawa, H Fujii and Y Sonoda
Leukemia 18: 566-574; advance online publication, December 18, 2003; doi:10.1038/sj.leu.2403211
Murine marrow cellularity and the concept of stem cell competition: geographic and quantitative determinants in stem cell biology FREE
G A Colvin, J-F Lambert, M Abedi, C-C Hsieh, J E Carlson, F M Stewart and P J Quesenberry
Leukemia 18: 575-583; advance online publication, January 29, 2004; doi:10.1038/sj.leu.2403268
Inactivation of the ARF–MDM-2–p53 pathway in sporadic Burkitt's lymphoma in children FREE
M Wilda, J Bruch, L Harder, D Rawer, A Reiter, A Borkhardt and W Woessmann
Leukemia 18: 584-588; advance online publication, December 18, 2003; doi:10.1038/sj.leu.2403254
Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas FREE
J J F Muris, C J L M Meijer, S A G M Cillessen, W Vos, J A Kummer, B A Bladergroen, M J J T Bogman, M A MacKenzie, N M Jiwa, L H Siegenbeek van Heukelom, G J Ossenkoppele and J J Oudejans
Leukemia 18: 589-596; advance online publication, December 18, 2003; doi:10.1038/sj.leu.2403240
Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma FREE
J Czarneski, Y C Lin, S Chong, B McCarthy, H Fernandes, G Parker, A Mansour, K Huppi, G E Marti and E Raveche
Leukemia 18: 597-606; advance online publication, January 8, 2004; doi:10.1038/sj.leu.2403244
N-(4-hydroxyphenyl)retinamide induces growth arrest and apoptosis in HTLV-I-transformed cells FREE
N Darwiche, A Hatoum, G Dbaibo, H Kadara, R Nasr, G Abou-Lteif, R Bazzi, O Hermine, H de Thé and Ali Bazarbachi
Leukemia 18: 607-615; advance online publication, December 18, 2003; doi:10.1038/sj.leu.2403245
Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma FREE
S M Ansell, B K Arendt, D M Grote, D F Jelinek, A J Novak, L E Wellik, E D Remstein, C F Bennett and A Fielding
Leukemia 18: 616-623; advance online publication, January 29, 2004; doi:10.1038/sj.leu.2403281
Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma FREE
S Kumar, T E Witzig, A Dispenzieri, M Q Lacy, L E Wellik, R Fonseca, J A Lust, M A Gertz, R A Kyle, P R Greipp and S V Rajkumar
Leukemia 18: 624-627; advance online publication, January 29, 2004; doi:10.1038/sj.leu.2403285
Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis FREE
N Giuliani, P Lunghi, F Morandi, S Colla, S Bonomini, M Hojden, V Rizzoli and A Bonati
Leukemia 18: 628-635; advance online publication, January 22, 2004; doi:10.1038/sj.leu.2403269
A novel recombinant bispecific single-chain antibody, bscWue-1 CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells FREE
D Hönemann, P Kufer, M M Rimpler, M Chatterjee, S Friedl, F Riecher, K Bommert, B Dörken and R C Bargou
Leukemia 18: 636-644; advance online publication, January 22, 2004; doi:10.1038/sj.leu.2403264
Spotlight Correspondence
Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration FREE
T Yokoyama, K Miyazawa, E Kurakawa, A Nagate, T Shimamoto, K Iwaya, S Akata, M Aoshima, H Serizawa and K Ohyashiki
Leukemia 18: 645-646; advance online publication, January 15, 2004; doi:10.1038/sj.leu.2403251
Impairment of heart rate variability control during arsenic trioxide treatment for acute promyelocytic leukemia FREE
A Takeshita, A Uehara, K Shinjo, K Naito, N Sahara, K Yamazaki, H Katoh, T Kamikawa, K Ohnishi, M Maekawa, H Hayashi and R Ohno
Leukemia 18: 647-648; advance online publication, December 11, 2003; doi:10.1038/sj.leu.2403248
Correspondence
CD38 expression on B-cell chronic lymphocytic leukemic cells is strongly correlated with vascular endothelial growth factor expression FREE
D McCabe, L Bacon, K O'Regan, C Condron, J R O'Donnell and P T Murphy
Leukemia 18: 649-650; advance online publication, January 29, 2004; doi:10.1038/sj.leu.2403282
Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study group FREE
H Kantarjian and J Cortes
Leukemia 18: 650; advance online publication, January 22, 2004; doi:10.1038/sj.leu.2403277
Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials FREE
L Pagano, A Pulsoni, M E Tosti, C Caramatti, R Cerri, P Falcucci, P Fazi, L Fianchi, B Martino, D Mattei, M Offidani, L Pacilli, E M Pogliani, B Rotoli, G Specchia, G Visani, M Vignetti, M T Voso, G Leone and F Mandelli for GIMEMA
Leukemia 18: 651-653; advance online publication, January 29, 2004; doi:10.1038/sj.leu.2403276
Chromosomal abnormalities clustering in multiple myeloma reveals cytogenetic subgroups with nonrandom acquisition of chromosomal changes FREE
B Sáez, J I Martín-Subero, F Guillén-Grima, M D Odero, F Prosper, J C Cigudosa, L Harder, M J Calasanz and R Siebert
Leukemia 18: 654-657; advance online publication, January 8, 2004; doi:10.1038/sj.leu.2403256
BRAF gene is not mutated in mismatch repair-proficient or -deficient plasma cell dyscrasias FREE
M Velangi, E Matheson, P Taylor, G Jackson, A G Hall and J A E Irving
Leukemia 18: 658-659; advance online publication, January 29, 2004; doi:10.1038/sj.leu.2403286
Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma FREE
F Ayuk, A Shimoni, A Nagler, R Schwerdtfeger, M Kiehl, H G Sayer, T Zabelina, A R Zander and N Kröger
Leukemia 18: 659-662; advance online publication, December 11, 2003; doi:10.1038/sj.leu.2403252
